CELU Overview

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.

Wall Street analysts forecast CELU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELU is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Celularity Inc revenue for the last quarter amounts to 5.28M USD, decreased -43.16

Celularity Inc. EPS for the last quarter amounts to -0.88 USD, increased 20.55

Celularity Inc (CELU) has 123 emplpoyees as of April 30 2026.

Today CELU has the market capitalization of 27.68M USD.